智飞生物(300122.SZ)：HK.3-JN.1新冠病毒mRNA疫苗获临床试验批准

Core Viewpoint - The company Zhifei Biological Products (300122.SZ) has received approval from the National Medical Products Administration for clinical trials of its self-developed HK.3-JN.1 mRNA vaccine aimed at preventing diseases caused by the novel coronavirus [1] Group 1 - The vaccine is developed by the company's wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd [1] - The approval allows the company to initiate clinical trials for the vaccine [1]